1. Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms;Awad;Ther. Adv. Neurol. Disord.,2009
2. Idec Biogen, 2013. TYSABRI (natalizumab) injection, for intravenous use. Prescribing Information. Available at: 〈http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/125104s033lbl.pdf〉. (Accessed 8 June 2016).
3. Biogen Idec Limited. TYSABRI SmPC. Available at:〈http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000603/WC500044686.pdf〉. (Accessed 8 June 2016).
4. The immune modulator FTY720 targets sphingosine 1-phosphate receptors;Brinkmann;J. Biol. Chem.,2002
5. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial;Calabresi;Lancet Neurol.,2014